Indication & Important
Safety InformationFull Prescribing
Information
Home page hero

THERE'S A LOT TO CONSIDER

WHEN PRESCRIBING AN

EXTENDED-RELEASE OPIOID

Abuse-deterrent properties do not prevent or reduce the risk of addiction.1

Abuse of OxyContin by the intravenous, intranasal, and oral routes is still possible.

Down arrow

Reference: 1. US Food and Drug Administration. Remarks delivered before FDA's scientific meeting on opioids. July 10, 2017. https://www.fda.gov/NewsEvents/Speeches/ucm566189.htm. Accessed February 21, 2018.

When you access any of our websites, related other parities’ websites, mobile applications, or any electronic service, we may use cookies and other technologies to automatically collect information regarding you and your device to assess user activity and preferences. We may also use third-party analytic tools to assist with the collection of information including, but not limited to, Google Analytics. By using this site, you agree to our use of these technologies in accordance with our Privacy Policy.